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patients. In this trial, 125 patients underwent LT between
2001 and 2007 at 11 US centers.
Methods: Database review.
Patients: Forty-five out of 125 patients (30%) undergoing
LT in this trial had HCC. These patients averaged 50 years of
age and the median native MELD at transplant was 15 (IQR
11–15). All patients were within Milan criteria at transplant
and only 1 patient had been previously downstaged. Hepatitis
C (HCV) was present in 30 of 45 patients.
Results: One and 3 year graft survivals for the HCC+/HIV+
patients were 82% and 67%, compared to 75% and 58% in
the HCC-/HIV+ patient group from the same trial (p ns).
Most grafts were lost due to HCV. At a median followup of
4.5 years, 4 patients (11%) developed HCC recurrence,
which occurred at a mean of 14 months after LT. Of the
recurrences one patient survived >24 months.
Conclusion: LT is an effective treatment for HCC in HIV+
patients, with survival rates similar to that of HIV+ patients
without HCC. Patient and graft survival are primarily deter-
mined by HCV status. HIV+ patients do not have excessive
risk of tumor progression after LT.
LO-I.04 PREDICTIVE FACTORS FOR
EXTRAHEPATIC RECURRENCE OF
HEPATOCELLULAR CARCINOMA
FOLLOWING ORTHOTOPIC LIVER
TRANSPLANTATION
A. Andreou, J. Pratschke, D. Seehofer
Department Of General, Visceral And Transplant Surgery,
Charite Campus Virchow Klinikum, Berlin,
DEUTSCHLAND
Background: Recurrence of hepatocellular carcinoma
(HCC) in patients treated with orthotopic liver transplanta-
tion (oLTX) is associated with diminished survival. Particu-
larly extrahepatic localization of HCC recurrence contributes
to poor prognosis.
Patients and Methods: Clinicopathological data of patients
who underwent oLTX for HCC between 1989 and 2010 in a
high-volume transplant center were retrospectively evaluated
and predictors of extrahepatic recurrence were identified.
Results: Three hundred and sixty-seven patients underwent
oLTX for HCC. After a median follow-up time of 77 months,
93 patients (25%) were diagnosed with a recurrence. Median
time to recurrence was 18.9 months. Recurrence was located
exclusively in the liver in 19 cases (20%) and 74 patients
(80%) had extrahepatic recurrence. Factors associated with
extrahepatic recurrence in multivariate analysis included
HCC beyond the Milan criteria (P < .0001) and the presence
of major vascular tumor invasion (MVI) (P = .035). In
patients with HCC beyond the Milan criteria who developed
a recurrence (n = 73), MVI was the only positive predictor of
extrahepatic recurrence in multivariate analysis (P = .0001).
In patients with HCC within the Milan criteria who recurred
after oLTX, DNA-index >1.5 (P = .04) was the only predic-
tive factor for extrahepatic recurrence.
Conclusions: Advanced HCC beyond the Milan criteria and
the presence of MVI are associated with an increased risk for
extrahepatic recurrence and are currently considered as
contraindications to oLTX. In patients with HCC within the
Milan criteria, the DNA-index represents a valuable prognos-
tic marker for the development of extrahepatic recurrence
and may support the selection of patients for intensive post-
operative tumor surveillance.
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OP-II.01 PANCREATIC DEBRIDEMENT
FOR NECROTIZING PANCREATITIS:
NATIONAL OUTCOMES AND
PREDICTORS OF MORTALITY
S. W. Ross, E. M. Hanna, R. C. Kirks, R. Seshadri,
J. B. Martinie, R. Z. Swan, D. A. Iannitti
Carolinas Medical Center, Division Of HPB Surgery,
Charlotte, NC
Background: Necrotizing pancreatitis often requires pan-
creatic debridement, which can result in a high rate of
morbidity and mortality. Risk factors that predispose patients
to post-operative complications or death are not well-defined.
Using a national surgical database, we sought to identify
pre-operative predictors of mortality after debridement.
Methods: The American College of Surgeon’s NSQIP data-
base was queried from 2005–2011 by CPT code for pancre-
atic debridement. Risk factors for complications and death at
30 days were examined using univariate tests and predictors
of mortality were identified using step-wise logistic
regression.
Results: 1,162 patients underwent pancreatic debridement.
On average patients were middle aged(54.9 ± 14.2 years),
male(70.0%), and obese(30.6 ± 8.0 kg/m2). The most
common comorbidities included diabetes(33.2%),
smoking(22.3%), COPD(6.5%), steroid use(4.0%) and
cardiac history (4.0%). Prior to surgery, 21.2% had ascites,
7.6% had acute renal failure, 14.7% had recent >10% body
mass loss, and 63.2% had pre-operative sepsis. Emergent
surgery occurred in 29.3%. Wound, general, and major com-
plications occurred in 7.2%, 56.6% and 31.3% respectively.
Mean length of stay was 34.1 ± 31.0 days. 30 day mortality
was 7.7%, and was higher in patients with COPD, cardiac
history, ascites, acute renal failure, steroid use, sepsis, older
age, higher BMI, and emergent operations(p < 0.05). The
table summarizes independent predictors of mortality iden-
tified using multivariate analysis.
Conclusion: Nationally, rates of adverse outcomes follow-
ing pancreatic debridement are high. Patients who are older,
with higher BMI, are on dialysis, have COPD, with
poor functional status, hypoalbuminemia, azotemia or
hyperbilirubinemia have increased odds of mortality follow-
ing debridement for necrotizing pancreatitis.
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OP-II.02 EXPERIENCE WITH
PANCREAS-SPARING DUODENECTOMY
FOR FAMILIAL ADENOMATOUS
POLYPOSIS
M. Dong, N. Ali, S. Reddy, C. O’Rourke, G. Morris-Stiff,
R. M. Walsh
Department Of HPB Surgery, Cleveland, OHIO
Introduction: Duodenal adenomas are a common finding in
patients with familial adenomatous polyposis (FAP) and
individuals with Spigelman stage IV adenomas are at high
risk of developing duodenal carcinoma. These patients are
traditionally treated by pancreatoduodenectomy (PD) though
an alternate approach is pancreas-sparing duodenectomy
(PSD). We report a 22-year experience with PSD for the
treatment of duodenal polyps in FAP.
Methods: A retrospective review was performed of a pro-
spectively maintained database containing all patients under-
going PSD from 1992 to 2013. Phone interviews were
conducted to confirm current status of patient at follow-up.
Results: Fifty-four patients underwent PSD during the
study period, all for Spigelman stage IV polyps. An unsus-
pected invasive cancer was found in one patient on final
pathology. The mean operative time was 305 ± 70 minutes
with a mean blood loss of 300 ± 170 mL. There was one
peri-operative mortality, unrelated to the operative pro-
cedure. Thirteen patients (24%) had an immediate post-
operative complication including eight (15%) biliary/
pancreatic leaks, and 1 (2%) enteric anastomotic leak.
Pancreatitis was observed in 4 (10%). 42(78%) of patients
were available for follow-up. Recurrent polyps were found in
16(34%). Of these, only 3(19%) patients required operative
intervention, two proximal jejunal resections and one PD for
development of a polyp at the ampullary anastomosis.
Conclusion: Our experience with PSD reinforces its value
as a definitive prophylactic procedure for duodenal polyposis
in FAP and allows for full preservation of pancreatic
function.
OP-II.03 THE EFFECT OF EARLY
POST-OPERATIVE NON-STEROIDAL
ANTI-INFLAMMATORY DRUGS ON
OUTCOMES FOLLOWING
PANCREATICODUODENECTOMY
R. Behman1,2, P. Karanicolas1,2, M. Lemke1,2, S. Hanna1,2,
C. Law1,2, N. Coburn1,2, J. Hallet1,2
1University Of Toronto, Toronto, ONTARIO; 2Odette
Cancer Centre, Toronto, ONTARIO
Introduction: Non-steroidal anti-inflammatory drugs
(NSAIDs) are used commonly for post-operative analgesia,
but can potentially impair healing. Their effect on
pancreaticoduodenectomy (PD) outcomes is unknown. We
sought to examine the impact of early post-operative
NSAIDs on pancreatic fistula (PF) after PD.
Methods: We reviewed our prospective pancreatectomy
database supplemented by medication administration
records, including all PDs from 2002 to 2012. Primary
outcome was occurrence of clinically significant (Grade
B-C) PF. Secondary outcomes included major morbidity
(Clavien grade III-V) and 90-day mortality. Patients were
compared based on early post-operative NSAIDs use (first 3
days following surgery) using univariate and multivariate
analyses. Sub-group analyses were conducted based on
NSAIDs type (ketorolac and COX2-inhibitor).
Results: We identified 251 PDs, of whom 127 (50.6%)
patients received NSAIDs postoperatively (15.1% ketorolac,
32.7%, COX2-inhibitor, 2.8% both). Use of any NSAIDs
was associated with a non-significant increase in PF (16.5%
Vs 11.3%%; p = 0.23), and no difference in major morbidity
and mortality. Use of ketorolac was not associated with an
increase in PF (8.7% Vs. 15.1%; p = 0.256). COX2-
inhibitors were associated with increased PF (20.2% Vs.
10.5%; p = 0.033), but no difference in major morbidity or
mortality. After adjusting for age, Charlson comorbidity
score, diagnosis, and estimated blood loss, use of COX2-
inhibitors was independently associated with PF (odds ratio
2.32; p = 0.026).
Conclusions: COX2-inhibitors are associated with PF in
the early postoperative period. While ketorolac appears
safe in this setting, caution is warranted with the use of
COX2-inhibitors.
OP-II.04 NEOADJUVANT THERAPY
WITH ANATOMICAL BORDERLINE
PANCREATIC DUCTAL
ADENOCARCINOMA. DOES IT
MAKE DIFFERENCE?
A. M. Zaki1, N. Rezaee1, J. He1, J. L. Cameron1,
K. Hirose1, T. M. Pawlik1, N. Ahuja1, M. A. Makary1,
H. E. Horeya2, M. J. Weiss1, C. L. Wolfgang1
1Johns Hopkins University School Of Medicine, Baltimore,
MARYLAND; 2Mansoura University School Of Medicine,
Mansoura, DAKAHLIA
Background: The benefit of neoadjuvant therapy over
a surgery-first approach in patients with borderline pancre-
atic ductal adenocarcinoma (PDAC) has not been well
defined.
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Aim: To compare postoperative outcomes of patients with
borderline PDAC who underwent pancreatectomy after
neoadjuvant treatment with those of patients who underwent
upfront surgery.
Methods: Between 2008 and 2014, 231 patients were iden-
tified as anatomical borderline PDAC. 117 of 231 (50.6%)
patients received neoadjuvant therapy and 114 (49.4%)
patients had a surgery-first approach. Univariate, multivariate
and survival analyses were performed.
Results: Compared to surgery first group, neoadjuvant
group was associated with smaller tumor size in the patho-
logical specimen (P < .001), lower incidence of metastatic
lymph nodes (39% vs. 80%; P < .001), less perineural inva-
sion (61% vs. 97%: P < .001), less micro-vascular invasion
(32% vs. 68%: P < .001), less vascular resection rate (31%
vs. 57%; P < .001) and a lower rate of positive resection
margin (32% vs. 44%; P < .055). Univariate analysis identi-
fied nodal status, lymph node ratio and tumor size as predic-
tors for survival. Multivariate analysis identified only lymph
node ratio (P = .005) as independent predictor of patient sur-
vival. Postoperative mortality and morbidity rates were
similar in the 2 groups. However, survival analysis starting
from date of first dose of neoadjuvant therapy versus date of
upfront surgery showed better median overall survival in
favor of the neoadjuvant group (44 months vs. 20 months;
P = .011).
Conclusion: Neoadjuvant treatment for borderline PDAC is
associated with better pathological outcomes and overall sur-
vival. Lymph node ratio can provide significant prognostic
information after pancreatectomy for patients with border-
line PDAC.
OP-II.05 PANCREATODUODENECTOMY
PROVIDES EFFECTIVE LONG-TERM
PAIN RELIEF FOR CHRONIC
PANCREATITIS IN SELECT PATIENTS AT
GREATER THAN 15 YEARS FOLLOW-UP
K. P. Croome, D. M. Nagorney, M. Tee, M. J. Truty,
K. Reid-Lombardo, F. G. Que, M. L. Kendrick,
M. B. Farnell
Mayo Clinic, Rochester, MN
Background: We have employed pancreaticoduo-
denectomy (PD) for selected patients with small duct, head-
dominant chronic pancreatitis (CP) with intractable pain.
Information examining very long term outcomes in patients
undergoing PD for CP is lacking.
Patients and Methods: All patients who underwent PD for
CP from 1976 to 2013 were reviewed. Surviving patients
were contacted for a follow-up questionnaire and SF-12
Quality of Life Survey.
Results: A total of 166 patients were identified (Cohort 1:
1976–1999(N = 105) and Cohort 2: 2000–2013(N = 61)).
Median time from presentation until surgery was signifi-
cantly longer in Cohort 2(2.09 years) compared to Cohort
1(1.13 years)(p = 0.017). A higher proportion of patients in
Cohort 2(98%) had intractable pain prior to surgery than in
Cohort 1 (82%)(p = 0.002). Prior to PD a higher proportion
of patients in Cohort 2 had undergone endoscopic stenting,
67% vs 10%(p < 0.001) and/or celiac plexus block 15% and
5%(p = 0.026). Median follow-up for all survey respondents
was 15 years. On the SF-12, mean physical component
score(PCS) was 43.8 ± 11.8 and mental component
score(MCS) was 54.3 ± 7.9. Patients were significantly
lower on the PCS(p < 0.001) and significantly better on the
MCS(p = 0.001) than the general US population. Mean pain
score out of 10 was significantly lower after surgery 1.6 ± 2.6
than before surgery 7.9 ± 3.5(p < 0.001). Diabetes developed
in 28% of patients who were not diabetic prior to surgery.
Conclusion: Although practice has changed so that patients
have a longer time from presentation until surgery as less
invasive techniques are attempted, PD appears to provide
effective long-term pain relief and acceptable quality of life
in appropriately selected patients with chronic pancreatitis
and intractable pain.
OP-II.06 GETTING THE FULL PICTURE:
SIGNIFICANCE OF INDETERMINATE
LUNG NODULES IN PANCREATIC
ADENOCARCINOMA
K. T. Hemingway1, E. Halpern2, P. V. Pandharipande3,
A. L. Warshaw1, C. Fernandez Del Castillo1,
K. D. Lillemoe1, C. R. Ferrone1
1Department Of Surgery-Massachusetts General Hospital,
Boston, MA; 2Department Of Biostatistics-Massachusetts
General Hospital, Boston, MA; 3Department Of
Radiology-Massachusetts General Hospital, Boston, MA
Objectives: Patients presenting with resectable pancreatic
adenocarcinoma (PDAC) often have indeterminate lung
nodules on pre-operative chest CT scans. The aim of this
study was to determine whether nodules on chest CT are
predictive of lung first metastases (LFM).
Methods and Materials: Retrospective clinicopathologic
data was recorded for patients undergoing resection of their
PDAC between 1993–2012 who also underwent a pre-
operative chest CT scan. Time to metastasis and overall sur-
vival (OS) were calculated.
Results: Of 792 patients who underwent surgical resection
of their PDAC, 171 underwent a pre-operative chest CT scan.
Median age was 67.7 years and 54.7% were female. Median
PDAC size was 30 mm. Indeterminate nodules were identi-
fied in 111 patients. Indeterminate lung nodules of 0–3 mm in
35 patients, 3–6 mm in 44 patients, 6–10 mm in 12 patients
and >10 mm in 14 patients. Lung-first metastasis (LFM)
developed in 20.7% of patients with nodules vs. 10.8% of
patients with no nodules (p = 0.142). Patients with LFM had
the longest median OS compared to patients developing
lung + liver (6.3%) or lung + local (5.4%) metastases
(32.7 mo vs 22.3 mo vs. 18.6 mo, respectively). The risk of
lung-first metastases did not increase with increasing size,
number, or location of indeterminate nodules, smoking
history or pre-operative Ca19-9. Of the 28 patients with
LFM, 6 underwent surgical removal of one or more nodules.
Conclusions: Neither the location, number, or size of inde-
terminate lung nodules on pre operative chest CT scans are
predictive of developing lung metastases as the first site of
metastatic disease.
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OP-II.07 READABILITY AND ACCURACY
OF ONLINE PATIENT MATERIALS FOR
PANCREATIC CANCER BY TREATMENT
MODALITY AND WEBSITE AFFILIATION
A. Storino1, M. Castillo-Angeles1, A. A. Watkins1,
C. Vargas1, J. Mancias1, A. Bullock1, A. Demirjian2,
A. J. Moser1, T. S. Kent1
1Beth Israel Deaconess Medical Center – Harvard Medical
School, Boston, MA; 2University Of California, Irvine,
Orange, CA
Introduction: Patients search online health information fre-
quently but there is little quality control. Patient/family
understanding of presented information may depend, partly,
upon readability and accuracy. This study was undertaken to
evaluate reading level and accuracy among commonly
searched websites about pancreatic cancer treatment options.
Methods: An online search on 5 pancreatic cancer treatment
modalities was conducted. Readability was measured by 9
standardized tests and accuracy was assessed by an expert
panel. Readability and accuracy were compared by treatment
modality and website affiliation by Kruskal-Wallis test.
Results: Significant differences existed by treatment modal-
ity for both readability and accuracy (Table 1), with surgery-
related websites having the lowest readability level.
Alternative therapy-related websites had the lowest accuracy.
Readability varied by affiliation, with lower readability for
non-profits than media-owned (p = 0.00001) and academic
center sites (p = 0.0001). Privately-owned websites had
lower readability than media sites (p = 0.009). Accuracy was
highest for government websites; government, academic, and
non-profit sites were more accurate than privately-owned or
media-owned websites (p = 0.0001). There was no associa-
tion between accuracy and readability level.
Conclusions: Although variation existed in both readability
and accuracy, improvement is needed throughout. The read-
ability level for all treatment modalities is higher than rec-
ommended, which may negatively impact patient/family
understanding of treatment options. Accuracy was reason-
able, except for alternative therapy websites. Website affilia-
tion impacted both readability and accuracy. Privately-owned
and media sites had lower accuracy. In accordance with
patient-centered care, improvement is needed in the quality
of online resources in order to empower patients in the
shared-decision making setting.
OP-II.08 ENGLISH AND SPANISH
LANGUAGE READABILITY OF ONLINE
PATIENT RESOURCES FOR
PANCREATIC CANCER
M. Castillo-Angeles, A. Storino, A. A. Watkins, C. R.
Vargas, J. F. Tseng, M. P. Callery, A. J. Moser, T. S. Kent
Beth Israel Deaconess Medical Center, Harvard Medical
School, Boston, MA
Introduction: 50% of cancer patients search the Internet for
health information. The NIH and AMA recommend that
patient-oriented health information should be written at a
sixth-grade reading level. We evaluated commonly-searched
English and Spanish-language pancreatic cancer websites in
light of these recommendations.
Methods: The top ten websites for “pancreas cancer” in
English and Spanish were identified in a patient-simulated
manner using the most-visited internet search engine. 122
English and 76 Spanish articles were assessed using ten
readability analyses. Spanish-language websites native to 3
representative Spanish-language countries with AHPBA
chapters were identified. Mean readability scores were deter-
mined for each article and website. T-tests were used to
compare reading levels by website, language, and country.
Results: Overall mean reading level across US websites was
12.4 ± 1.42 (English) and 10.5 ± 0.95 (Spanish). Mean read-
ability by website ranged from 9.5 to 15.2 in English, and
from 8.6 to 12.3 in US Spanish. Argentine, Chilean, and
Mexican websites had mean reading levels 9.7, 10.9, and 11
respectively. Spanish websites in each country were signifi-
cantly easier to read than those in English (Figure 1).
Conclusion: Commonly searched online pancreatic cancer
resources in English and Spanish exceed the recommended
sixth grade reading level. Spanish-language websites,
US-based or not, were significantly easier to read than
English-language sites, though still above the recommended
6th grade level. With the growing focus on patient-centered
care, attention should be paid to ensuring availability of
information at a level understandable by the general public.
More easily understandable materials may facilitate patient
participation in shared decision-making.
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OP-II.09 PLASMA CANCER ANTIGEN
19-9 (CA19-9) LEVELS DIFFERENTIATE
PATIENTS WITH MALIGNANT
INTRADUCTAL PAPILLARY MUCINOUS
NEOPLASM (IPMN) FROM THOSE WITH
IPMN ALONE
T. K. Nguyen, D. Joyce, G. A. Falk, S. Chalikonda,
G. Morris-Stiff, R. M. Walsh
Cleveland Clinic Foundation, Cleveland, OH
Introduction: Malignant transformation is a recognized
complication of IPMNs, in particular when the disease
affects the main pancreatic duct. However they are often only
recognized during histopathological examination of resec-
tion specimens. Plasma CA19-9 has potential use in the
diagnostic work-up of pancreatic adenocarcinoma but has
not been well investigated in IPMN. The aim of this study
was to evaluate the role of CA19-9 in differentiating between
malignant IPMN (invasive [IPMN Ca] and high grade dys-
plasia [HGD]) IPMN from those with IPMN and low/
moderate (LGD & MGD) dysplasia.
Methods: The institutional pancreatic cyst database was
interrogated to identify all patients with a histopathological
diagnosis of IPMN. Patients were sub-divided into three cat-
egories based on the degree of neoplastic change: IPMN
carcinoma; IPMN HGD; and IPMN LGD&MGD. Ca19-9
levels were assessed in relation to the 3 categories. The
IPMN Ca and IPMN HGD were then co-assessed.
Results: During the period January 2000 to December 2013,
158 patients underwent resection, with final histopathology
indicating: IPMN [n = 45] carcinoma, IPMN HGD [n = 24];
and IPMN LGD/MGD [n = 89]. There was no difference in
comparing incidental versus pre-operatively diagnosed can-
cers or when comparing main duct and side-branch IPMNs.
Conclusions: Plasma CA19-9 is independently valuable in
the evaluation of HGD and carcinoma arising in the setting of
IPMN.
[Correction added on 24 February 2015, after online publica-
tion. Author’s initial changed from R. Walsh to R.M. Walsh]
OP-II.10 PANCREATIC NECROSIS: A
SINGLE INSTITUTIONS REVIEW OF
PRACTICAL ADHERENCE TO A
STEP-UP APPROACH
S. Downs-Canner, B. Boone, J. Steve, A. Zureikat,
K. K. Lee, H. J. Zeh, M. Hogg
University Of Pittsburgh Medical Center, Pittsburgh, PA
Introduction: Level 1 evidence demonstrated the “step-up”
approach to infected pancreatic necrosis improves outcomes.
We examined our institution’s compliance with this approach
and its impact on outcomes.
Methods: We performed a retrospective review of the index
admission of all patients with necrotizing pancreatitis treated
in 2012 at a tertiary referral academic medical center.
Results: 41 patients (median age 52, 75% male) were
treated for necrotizing pancreatitis. 80% were transferred a
median of 3 days from presentation. By the revised Atlanta
Classification, 23 (56%) had severe acute pancreatitis and 19
(46%) had suspected/confirmed infected necrosis. Of those
infected, 18 (95%) required pancreatic drainage procedures;
10 (56%) underwent step-up (Table). Median time from pres-
entation to first pancreatic drainage was 1 day (step-up = 0.5
days versus surgery first = 4.5 days). Five (50%) of step-up
went on to surgery a median of 1 day later. Nine (47%) had
multi-system organ failure (step-up = 30% versus surgery
first = 75%). Median length of stay was 23 days for step-up
versus 21 days for surgery first. ICU admission rate was 90%
for step-up versus 80% for surgery first. In-hospital mortality
was 20% in step-up and 12.5% in surgery first. Overall sur-
vival for all necrotizing pancreatitis patients was 78% and
71% of deaths were related to pancreatitis. Pancreatitis
related readmission rate was 59% (step-up = 30% versus
surgery = 88%).
Conclusion: Step-up adherence was 56%; however, half of
those went on to surgery. Further analysis is necessary to
determine if the subset of patients undergoing surgery first
represent deviations from level 1 recommendations or medi-
cally appropriate deviations.
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OP-II.11 NATIONAL DISPARITIES IN
MINIMALLY INVASIVE SURGERY FOR
PANCREATIC CANCER
E. M. Gabriel1, P. Thirunavukarasu1, K. Attwood2,
S. Hochwald1, B. Kuvshinoff1, S. Nurkin1
1Roswell Park Cancer Institute, Buffalo, NY; 2Roswell Park
Cancer Institute, Buffalo, NY
Introduction: Social and racial disparities have been related
to differences in access to care. This study investigated pat-
terns in minimally invasive surgery (MIS) across different
social, racial and geographic populations of patients with
pancreatic cancer.
Methods: We utilized the National Cancer Database, 2004
to 2011, to identify patients with pancreatic cancer who
underwent surgery through either an open, laparoscopic or
robotic approach. Multivariate analysis was performed to
characterize differences in patient demographics in relation
to surgical approach.
Results: A total of 11,464 patients were identified. The
initial surgical approach included 82.5% open (9,461),
15.8% laparoscopic (1,815) and 1.6% robotic (188). Table 1
shows the results of our analysis. Race was not statistically
significant across the different surgical approaches. There
was a trend toward increased MIS in patients with private
insurance. Academic centers performed more MIS compared
to community cancer programs. On multivariate analysis,
only national location was shown to be a statistically signifi-
cant factor associated with increased rates of MIS. Patients in
the Middle Atlantic region of the US were most likely to have
robotic surgery. Regarding laparoscopic surgery, the Moun-
tain and West South Central states had the lowest rates of
laparoscopic procedures, but among the other national
regions there were no statistically significant differences.
Conclusions: Minimally invasive approaches for pancreatic
cancer comprise 17.5% of surgical procedures. Race and
insurance status were not statistically significant factors asso-
ciated with MIS. Although academic centers performed most
of the MIS, specific geographic regions comprised the only
statistically significant factor on multivariate analysis.
OP-II.12 WHAT IS THE COMPLETENESS
OF PATHOLOGY REPORTS FOR
RESECTED PANCREATIC
ADENOCARCINOMA SPECIMENS? A
POPULATION-BASED ANALYSIS
A. El-Sedfy1,2, D. J. Kagedan1,3, E. Shin1, R. Raju1,
M. E. Dixon1,4, M. Elmi 1,3, C. Rowsell3, Q. Li1,3,
N. Mittmann1,3, N. G. Coburn1,3
1Sunnybrook Research Institute, Toronto, ONTARIO; 2Saint
Barnabas Medical Center, Livingston, NJ; 3Sunnybrook
Health Sciences Centre, Toronto, ONTARIO; 4Maimonides
Medical Centre, New York, NY
Introduction: Following oncologic resection, pathology
reports provide critical information for determining progno-
sis and directing treatment. However, reports are often
incomplete. We assessed pathology report completeness
from pancreatic adenocarcinoma (PAC) resections on a
population level.
Methods: All patients who underwent resection for PAC in
Ontario between 2005 and 2010 were identified using pro-
vincial databases. Pathology reports were evaluated for com-
pleteness based on the College of American Pathologists
(CAP) 2012 Protocol. Portal (PV) and superior mesenteric
vein (SMV) resections identified from physician billing
codes were compared to the corresponding pathology report.
Results: 475 patients had available pathology reports for
review. 421 were pancreaticoduodenectomy and 54 were
distal pancreatectomy. CAP pathologic variables and the per-
centage of reports missing each is as follows: T stage 0.8%;
N stage 0.4%; number of lymph nodes examined 3.4%;
margin status 2.7%; tumor grade 1.7%; lymphovascular inva-
sion 20.2%; perineural invasion 13.5%; microscopic tumor
extension 5.5%. 32.4% of pathology reports (n = 156)
revealed R1 resection. 21.4% of reports for specimens with
R0 resection (n = 308) were missing margin distance. Based
on billing, 122 patients underwent PV/SMV resections,
whereas only 47 (38.5%) were reported in their pathology
reports. Thirty patients were found to have pathologic evi-
dence of PV/SMV resection, but not based on billing.
Conclusion: Histologic characteristics and margin distances
are frequently missing from PAC pathology reports. High
rates of R1 resections exist, as well as discrepancies regard-
ing reporting of major vein resections between billing and
pathology reports, which holds substantial implications for
utilization of pathology reports for determination of
PV/SMV resection.
OP-II.13 COMPARATIVE ANALYSIS OF
INSTITUTIONAL CLINICAL PATHWAYS
FOR MANAGEMENT OF BORDERLINE
RESECTABLE PANCREATIC CANCER
O. M. Rashid1, J. M. Pimiento1, P. Nguyen1, G. Springett1,
P. Hodul1, S. Hoffe1, R. Shridhar1, B. L. Johnson2, K. Illig2,
P. A. Armstrong2, W. J. Fulp1, M. P. Malafa1
1H. Lee Moffitt Cancer Center And Research Institute,
Tampa, FL; 2University Of South Florida, Tampa, FL
Background: Currently there is no consensus combination
therapy clinical pathway (CP) for the management of border-
line resectable pancreatic adenocarcinoma (BPA) based on
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randomized prospective studies, therefore, BPA CP’s vary by
institution. We recently reviewed outcomes of our BPA CP
and now seek to compare results at other centers to further
evaluate optimal therapy.
Methods: We performed a literature review of all BPA CP
reports, excluding case reports and feasibility studies. BPA
diagnostic criteria, pancreatectomy rate, margin status,
pathologic response (grade IIa-IV) rate (PR), disease free
(DFS), disease specific (DSS), and overall survival (OS)
were reviewed and compared to our institutional data.
Standard statistical methods were used for statistical
comparison.
Results: There were three studies which met inclusion cri-
teria (Table). Including the 101 patients treated at our insti-
tution, 279 entered 4 CP’s. 175(59%) met NCCN/AHPBA
BPA diagnostic criteria, 144(41%) MDACC Type A. The CP
regimens are listed (Table). With 95% confidence, resection
rate at our institution was 44.2–64.4% versus 27.7–49.3%
with CP 1, 16.6–46.5% with CP 2, and 35.8–61.3% with CP
3. With 95% confidence, the PR at our institution was 69.9–
93.7% versus 55.2–63.5% with CP 1, 77.7–89.0% with CP2,
and 8.6–10.7% with CP3. DFS, DSS, and OS are reported
(Table).
Conclusions: A comparative analysis of outcomes demon-
strates that many BPA patients benefit from the reported
CP’s. However, the differences in reported resection and
pathologic response to treatment rates between institutional
CP’s warrant further investigation to determine optimal
therapy.
OP-II.14 DOMAIN-BASED ASSESSMENT
OF THE LEARNING CURVE FOR NEW
SURGICAL TECHNOLOGY:
ROBOT-ASSISTED VS. OPEN DISTAL
PANCREATECTOMY
S. Klompmaker, A. A. Watkins, W. J. Van Der Vliet,
S. J. Thoolen, A. Storino, M. Castillo-Angeles, J. F. Tseng,
M. P. Callery, T. S. Kent, A. J. Moser
Beth Israel Deaconess Medical Center, Harvard Medical
School, Boston, MA
Introduction: The Learning Curve for minimally-invasive
surgery monitors operating time, conversion rate, and incre-
mental cost as surrogate markers of proficiency and outcome.
We expanded this concept to include four aggregate domains
for new technology assessment (Table 1) based on Institute
of Medicine principles to evaluate overall risk/benefit. The
initial Learning Curve for robot-assisted distal pancreatec-
tomy (RADP) was compared to unmatched consecutive open
DP (ODP) at an expert center.
Methods: Unmatched comparison between 29 RADP and
169 consecutive ODP performed between 2006–2012 prior
to implementation of RADP. Cumulative treatment burden at
90 days was assessed. Propensity scoring controlled for
selection bias.
Results: No differences in age, gender, race, Charlson
Comorbidity Index, suspected pathology, tumor location, or
size were observed between the RADP and ODP cohorts.
Within the efficiency domain, RADP patients had a reduced
90-day total hospital stay (6 vs. 7 days, p = .002), but longer
mean operative time as compared to ODP patients (p < .001).
Cumulative morbidity and oncological efficacy for malig-
nancy was similar to ODP within the limits of sample size.
Safety, as measured by blood loss and laparotomy rate
(3.3%), was improved following RADP compared to ODP.
Propensity-scored sensitivity analysis did not alter these
results.
Conclusion: Domain-based evaluation of the initial RADP
learning curve was comparable to the established phase of
ODP in consecutive patients at an expert center. Operating
time and associated costs should be re-evaluated in the
context of reduced total hospital stay and increased patient
eligibility for the minimally-invasive approach. Prospective
validation of these metrics is required.
OP-II.15 TOTAL PANCREATECTOMY
FOR PANCREATIC ADENOCARCINOMA
IS ASSOCIATED WITH EQUIVALENT
PERI-OPERATIVE MORTALITY AND
LONG TERM SURVIVAL AS COMPARED
TO PARTIAL PANCREATECTOMY
E. H. Baker1, R. M. Seshadri1, M. A. Templin2,
R. Z. Swan1, J. B. Martinie1, D. A. Iannitti1
1Department Of General Surgery, Division Of HPB
Surgery, Carolinas Medical Center, Charlotte, NC;
2Dickson Advanced Analytics Group, Charlotte, NC
Introduction: Historically, total pancreatectomy (TP) for
pancreatic adenocarcinoma (PAC) has been performed for
large or advanced tumors but carries inherent significant
postoperative morbidity secondary to endocrine and exocrine
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insufficiency. Questions regarding postoperative mortality
and long term survival remain important when comparing
utility of TP to partial pancreatecomy (PP) procedures such
as pancreaticoduodenectomy (PD) or distal pancreatectomy
(DP) for pancreatic cancer.
Methods: Retrospective analysis of the National Cancer
Data Base between the years 1998–2011 was performed.
224,335 patients were identified with diagnosis code of PAC;
128,368 patients had relevant data from 1998–2006 and were
eligible for 5 year survival analysis. Chi-square, t-test,
Kaplan-Meier curves and log rank tests were used for statis-
tical analysis.
Results: 16,744 patients underwent surgical resection for
PAC during the study period. 1,954 patients underwent TP
while 16,111 underwent PP (959 DP and 13,357 PD). Rates
of TP increased during the study period (164 in 1998 to 295
in 2006). Mean tumor size was 38 mm for TP and 34.8 mm
for PP (p = 0.001). More lymph nodes were examined fol-
lowing TP (11.8 vs 10.8, p < 0.001). 30 day mortality rates
following TP were similar to PP (6.05% vs 5.35%, p = 0.20).
When compared stage for stage, there were no differences in
30 day mortality between groups. Median overall survival
following TP was 14.98 months vs 15.64 months for PP
(p = 0.16). No difference was seen in long term overall sur-
vival when patients were compared stage for stage.
Conclusions: Post-operative mortality and long term overall
survival rates are similar between TP and PP procedures.
OP-II.16 PREDICTORS OF PROGRESSION
OF LOCALLY ADVANCED PANCREATIC
CANCER ON NEOADJUVANT
CHEMOTHERAPY
J. B. Rose1, F. G. Rocha1, A. Alseidi1, T. Biehl1, B. Lin2,
V. Picozzi2, S. Helton1
1Virginia Mason Medical Center, Section Of Hepatobiliary
Surgery, Seattle, WA; 2Virginia Mason Medical Center,
Department Of Hematology/Oncology, Seattle, WA
Introduction: Neoadjuvant treatment for patients with
locally advanced pancreatic adenocarcinoma (LAPD) is
becoming more widely utilized and may be associated with
improved survival. However, even with careful patient selec-
tion, many patients do not undergo curative resection due to
disease progression. The objective of the present study is
to identify predictors of disease progression prohibiting
resection.
Methods: A retrospective review was performed on all
patients with LAPD at a high volume tertiary hospital
between January 2008 and August 2014 who received
extended neoadjuvant gemcitabine/docetaxel chemotherapy.
Clinicopathologic predictors of disease progression prohib-
iting resection were determined by univariate and multivari-
ate logistic regression analysis.
Results: Eighty-four patients with LAPD were initiated on
neoadjuvant chemotherapy. 16 patients (19%) progressed on
treatment by RECIST criteria (9 distant, 7 local). Multivari-
ate logistic regression analysis found that sex, age by
quartile, McGill-Brisbane score, clinical stage III, or multi-
vessel involvement were not predictive of progression pro-
hibiting resection. However, tumor size (OR 2.6 [1.3–5.5])
and lack of at least a 50% decrease in CA19-9 levels (OR
13.2 [2.5–69.1]) were. On sub-analysis, CA19-9 decrease
<50% remained predictive for any progression while tumor
size predicted distant progression only. A receiver operating
characteristic curve showed that tumor size >3 cm was 87%
sensitive for progression (AUC 0.785).
Conclusion: LAPD patients undergoing neoadjuvant
chemotherapy with tumors >3 cm or that exhibit less than
50% reduction in CA 19-9 maybe at higher risk for progres-
sion on chemotherapy. Patients with these risk factors may
benefit from additional treatment prior to an attempt at
resection.
OP-II.17 SURGERY VERSUS
NON-OPERATIVE MANAGEMENT OF
PANCREATIC ADENOCARCINOMA
WITH SMA INVASION
P. Thirunavukarasu, E. Gabriel, B. Kuvshinoff,
S. Hochwald, S. Nurkin
Roswell Park Cancer Institute, Buffalo, NY
Background: Pancreatic adenocarcinoma (PDAC) invading
the Superior Mesenteric Artery (SMA) is traditionally con-
sidered unresectable, with surgery offered to select patients.
We evaluated outcomes of surgery versus non-operative
management.
Methods: Data for patients with SMA-invading PDAC
without evidence of distant metastases was extracted from
the National Cancer Database, 1998–2006.
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Results: Of 3,445 patients, 227 (6.9%) had surgery,
specifically pancreaticoduodenectomies (73.2%), distal
pancreatectomies (14.5%) and total pancreatectomies
(12.3%). Overall R0 resection rate was 43.7%. Median hos-
pital stay was 9 days, 30-day mortality – 7.0%, and 30-day
readmission rate – 8.7%. In patients who underwent surgery
plus systemic therapy, median overall survival (OS) was 21
months when margin-negative and 13.6 months when
margin-positive (p < 0.001). In contrast, among patients who
underwent surgery alone, OS was uniformly poor regardless
of margin status (8.3 vs 6.7 months, p = 0.09). Patients with
R0 resection plus systemic therapy had significantly better
OS compared to patients in whom surgery was not recom-
mended (e.g.: due to comorbidities) or given systemic
therapy alone despite recommendation for surgery (Figure
1). Among patients without comorbidities, R0 resection plus
systemic therapy had significantly better survival than sys-
temic therapy alone (22.2 months vs. 11.4 months, p < 0.01).
The operative mortality of patients with ≤1 comorbidity
was lower than with ≥2 comorbidities (6.0% vs. 12.6%,
p = 0.05).
Conclusion: For appropriate patients with SMA-invading
PDAC, a combination of R0 resection with systemic therapy
offers the best outcome. Given the higher mortality, these
operations should be offered selectively in specialized
centers.
OP-II.18 EARLY DRAIN REMOVAL IS A
BEST PRACTICE IN SELECTED
PANCREATIC SURGERY PATIENTS
H. A. Pitt1, B. L. ZarZaur2, S. W. Behrman3,
E. M. Kilbane2, B. L. Hall4, A. Parmar5, R. S. Riall5
1Temple University School Of Medicine, Philadelphia, PA;
2Indiana University School Of Medicine, Indianapolis, IN;
3University Of Tennessee College Of Medicine, Memphis,
TN; 4Washington University School Of Medicine, St. Louis,
MO; 5University Of Texas Medical Branch, Galveston, TX
Background: The morbidity of pancreatic surgery remains
unacceptably high. Recent reports suggest that drain man-
agement may influence postoperative complications. While
early drain removal may improve outcomes, pancreatic sur-
geons have been slow to adopt this practice. Therefore, the
aim of this analysis was to compare outcomes when drains
were removed early or late after pancreatic surgery.
Methods: Data were gathered through the American
College of Surgeons – National Surgical Quality Improve-
ment Program (ACS-NSQIP) Pancreatectomy Demonstra-
tion Project (PDP). Over a 14-month period, 2,805 patients
underwent a pancreatoduodenectomy, distal pancreatectomy,
total pancreatectomy or pancreatic enucleation at 43 institu-
tions. After exclusion of patients without drains or data on
drain removal, 1,841 patients were available for analysis.
Early drain removal was defined as on or before POD#3.
Early drain patients (n = 148, 8.1%) were younger, had
more women and were less likely to undergo a
pancreatoduodenectomy. Therefore, propensity score match-
ing and sensitivity analyses were performed. Outcomes were
determined by ACS-NSQIP and PDP definitions. Standard
statistical tests were applied.
Results: After propensity score matching early (n = 127)
and late (n = 127) drain removal patients were well-balanced
for age, gender, BMI, serum albumin, ASA class, operation
type, time and approach, vascular resection, gland texture,
duct size, pathology and POD#1 drain amylase. Outcomes
are presented in the table.
Conclusions: This analysis suggests that early drain
removal is associated with reduced morbidity following
pancreatic surgery. Early drain removal should be considered
in selected pancreatectomy patients.
OP-II.19 751 CONSECUTIVE
PANCREATICO-DUODENECTOMIES AT
A TERTIARY CARE CENTRE: MAKING A
CASE FOR STANDARDIZATION AND
CENTRALIZATION
E. Pai, A. Mitra, S. Patkar, M. Goel, S. V. Shrikhande
Tata Memorial Hospital, India, Mumbai, MAHARASHTRA
Background: The outcome of Pancreatico-
duodenectomy(PD) has been closely linked to hospital
volume and experience. The low incidence of pancreatic
cancer, coupled with few specialized Hepato-Pancreatico-
Biliary teams and lack of referral patterns and service cen-
tralization, contribute to sparse data from the Indian
subcontinent.
Methods: Prospective database of PDs from 1992 to 2014
was evaluated retrospectively over 4 time periods based on
changing practice trends: A (1992–2001), B (2003-July
2009), C (August 2009-December 2011) and D (January
2012-August 2014). Peri-operative parameters were com-
pared using SPSS v.21.0.
Results: 751 patients underwent PD. The average resections
increased from 14 to 94, over periods A to D, respectively.
While post-operative pancreatic fistula(POPF) rates increased
from 16% to 21.5% over periods A to D, the incidence of bile
leaks and post-pancreatectomy hemorrhage declined to 0.8%
and 3.9%, respectively. Morbidity and hospital stay was more
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in period D compared to B and C, but mortality declined from
6.3% to 2.8% over periods A to D. Overall series morbidity
and mortality was 35.2% and 4.5%, respectively.
Conclusion: This series represents the largest single-centre
experience with PD from India and the surrounding region.
The higher morbidity in period D is likely attributable to a
combination of increasing surgical complexity and reduced
selection bias. The gradually increasing experience should
serve as a benchmark for developing dedicated pancreatic
surgery teams even in regions of low incidence of pancreatic
cancer where the need for training and centralization is
greater compared to high incidence regions, such as USA and
Europe.
OP-II.20 LEAKAGE OF AN
INVAGINATION
PANCREATICOJEJUNOSTOMY MAY
HAVE LETHAL CONSEQUENCES
H. Lavu1, S. W. Keith 1, E. M. Kilbane3, A. Parmar4,
B. L. Hall 5, H. A. Pitt2
1Thomas Jefferson University, Philadelphia, PA; 2Temple
University School Of Medicine, Philadelphia, PA; 3Indiana
University Health, Indianapolis, IN; 4University Of Texas
Medical Branch, Galveston, TX; 5Washington University
School Of Medicine, St. Louis, MO
Background: No consensus exists regarding the
most effective form of pancreaticojejunostomy following
pancreatoduodenectomy. The aim of this analysis was to
determine whether the type of pancreaticojejunostomy influ-
ences morbidity or mortality.
Methods: Data were gathered through the American
College of Surgeons-National Surgical Quality Improvement
Program, Pancreatectomy Demonstration Project. Over 14
months, 1,781 patients underwent a pancreatoduodenectomy
(PD) at 43 institutions. After exclusion of patients undergo-
ing minimally invasive PD and those without information on
gland texture or duct size, 890 patients were analyzed.
Patients were divided into duct-to-mucosa (n = 734, 82%)
and invagination (n = 156, 18%). Type of pancreati-
cojejunostomy (PJ) was then included in eight separate mor-
bidity and mortality multivariable analyses.
Results: Invagination patients had higher serum albumin
(p < 0.01) lower BMIs (p < 0.01) and preoperative serum
bilirubin (p < 0.02), were less likely to have a preoperative
biliary stent (p < 0.01) or chemotherapy (p < 0.04), were
more likely to have a soft gland (p < 0.01) and were
less likely to undergo pylorus preservation (p < 0.01).
Multivariable analyses demonstrated that age, gender, BMI,
preoperative albumin and biliary stents, gland texture and
pancreatic duct size were related (p < 0.05) to multiple post-
operative morbidity outcomes. PJ anastomosis type was not
associated with morbidity but did affect mortality (duct-to-
mucosa vs. invagination Odds Ratio 0.22, p < 0.01). Among
patients who developed a pancreatic fistula, none of the 119
duct-to-mucosa compared to five of 20 invagination patients
died (p < 0.01).
Conclusions: Patients who undergo a pancreatico-
jejunostomy (PJ) by duct-to-mucosa or invagination differ
with respect to pre- and intra-operative variables. When an
invagination PJ leaks, the consequences may be lethal.
OP-II.21 SHOULD ACUTE PANCREATITIS
BE AN INDICATION TO RESECT IPMN?
J. L. Cioffi, S. J. Lee, J. A. Waters, C. M. Schmidt,
A. Nakeeb, M. G. House, E. P. Ceppa, N. J. Zyromski
Indiana University, Indianapolis, IN
Introduction: Intraductal papillary mucinous neoplasms
(IPMN) cause acute pancreatitis (AP) more commonly than
generally appreciated. The natural history of IPMN with AP
is unclear, and whether an episode of AP should be an indi-
cation for surgery in the setting of IPMN is controversial. We
sought to determine the natural history of IPMN causing AP.
Methods: 348 patients with pathologically proved, resected
IPMN were analyzed. Patients with single versus multiple
episodes of AP were compared to determine clinical and
pathological differences between these groups.
Results: 114 (33%) IPMN patients had at least 1 episode of
AP. Among IPMN/AP patients, 22 (19%) had more than one
episode of AP. IPMN type (main duct, branch duct, mixed
type), location (head versus body/tail), and size were similar
between patients with single versus multiple AP episodes.
Duration of symptoms related to IPMN was significantly
longer for multiple AP patients (single episode 17 months,
multiple episodes 37 months). Invasive carcinoma was
present in 13 (11%) of all IPMN/AP patients, and was more
common in patients with multiple AP episodes (23%) than
those with a single AP episode (9%).
Conclusions: Acute pancreatitis occurs in 33% of patients
with resected IPMN, 19% of whom had multiple AP episodes
prior to resection. Patients with multiple AP episodes were
more likely to harbor invasive carcinoma compared to those
with a single episode of AP. These data support early resec-
tion of IPMN patients who develop acute pancreatitis.
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OP-II.22 ACCURACY OF PREOPERATIVE
IMAGING FOR VASCULAR
INVOLVEMENT IN LOCALLY
ADVANCED, BORDERLINE RESECTABLE
PANCREATIC ADENOCARCINOMA
FOLLOWING NEOADJUVANT
CHEMOTHERAPY
J. Clanton, J. B. Rose, A. Alseidi, T. Biehl, S. Helton,
F. Rocha
Virginia Mason Medical Center, Seattle, WA
Background: Radiographic imaging with arterial/venous
phase, thin-slice computed tomography (MDCT) and endo-
scopic ultrasound (EUS) are utilized for assessment and
staging of locally advanced, borderline resectable pancreatic
adenocarcinoma (BR-LAPD). Neoadjuvant therapy followed
by pancreaticoduodenctomy with vascular resection is typi-
cally required for BR-LAPD. However, little is known about
the correlation of MDCT and EUS findings with need for
vascular resection and pathologic invasion.
Methods: A retrospective review of a prospectively-
maintained database of consecutive patients with BR-LAPD
treated with neoadjuvant chemotherapy at our institution
between 2011 and 2014 was performed. MDCT and EUS
results were compared to operative findings and the final
pathologic reports regarding vascular involvement.
Results: A cohort of 33 patients underwent staging by
MDCT and EUS followed by neoadjuvant chemotherapy and
successful resection. All patients were reported to have
venous involvement on CT, EUS, or both. Based on preop-
erative imaging and operative findings, a venous resection
was performed in 15/33 (45.5%) patients, but histological
evidence of vascular invasion was only noted in 6/33 (18.2%)
pathologic specimens. These six patients were noted to have
vascular invasion on both CT and EUS. CT demonstrated
vascular involvement without EUS confirmation in 4/33
(12%) patients, while EUS demonstrated vascular involve-
ment without CT confirmation in 3/33 (9%) patients. None of
these patients had true pathologic vascular invasion.
Conclusion: CT and EUS can be complementary modalities
to detect BR-LAPD, but may overestimate the actual
incidence of venous involvement. This may be due to inher-
ent limitations of these techniques versus a true downstaging
effect of neoadjuvant chemotherapy.
OP-II.23 DISTAL PANCREATECTOMY
PERFORMED BY HIGH VS LOW
VOLUME SURGEONS IN A LARGE
INTEGRATED HEALTH CARE SYSTEM:
A RISK ADJUSTED ANALYSIS
S. Woo, A. Difronzo
Kaiser Permanente Los Angeles Medical Center, Los
Angeles, CALIFORNIA
Introduction: Improved outcomes for pancreatectomy are
observed when performed at high-volume centers. The study
objective was to compare predicted and actual risk-adjusted
outcomes of distal pancreatectomy (DP) performed by high
vs low volume surgeons in an integrated health care system.
Methods: A retrospective review of patients having DP
from 2005–2013. A standardized risk calculator was used to
predict risk of complications and mortality. The Clavien
grading system was used for actual complications. High
volume was 7 or more DP per year.
Results: 50 surgeons performed 247 DP. 3 high volume
surgeons performed 54 cases. In the low volume cohort, 193
DP were performed (median 2 per surgeon). The calculated
risk of any complication and risk of mortality was no differ-
ent between the two groups, but was significantly lower
than actual observed complications. There were more
laparoscopic (56 vs 33%, p = 0.001) and spleen-preserving
cases in the high volume group (59 vs 18%, p < 0.001). There
was a significant difference in overall actual 60-day compli-
cations: 33% in the high volume cohort vs 52% (p = 0.008).
There were fewer Clavien grade 1/2 complications (15 vs
37%, p < 0.001), and less postoperative pancreatic fistula
(PPF) (11% vs 33%, p = 0.0009) in the high volume group.
There was no difference in mortality between the groups.
Conclusion: Distal pancreatectomy performed by high
volume surgeons in a large health care system results in
decreased risk-adjusted overall morbidity including PPF.
Some observed differences may be related to greater use of
laparoscopy and splenic preservation.
OP-II.24 PORTAL VEIN THROMBOSIS
AFTER TOTAL PANCREATECTOMY AND
AUTOLOGOUS ISLET CELL
TRANSPLANTATION
W. P. Lancaster, D. B. Adams, K. A. Morgan
Medical University Of South Carolina Department Of
Surgery, Charleston, SC
Introduction: Portal vein thrombosis (PVT) is a rare com-
plication of total pancreatectomy with autologous islet trans-
plantation (TPIAT). Little is reported about the risk factors,
consequences, or treatment for this complication.
Methods: A retrospective review and analysis of a
prospectively-collected database of patients undergoing
TPIAT from March 2009 to August 2014 was conducted.
Two-tailed t-tests were used comparing continuous data and
Fisher’s exact test comparing categorical data.
Results: 135 patients (102 women,76%) underwent TPIAT;
Nine(7%) had PVT. All patients with PVT were women.
There were no differences in age or islet equivalents trans-
planted in patients with and without PVT. Mean BMI of
patients with PVT was lower than those without (21.8 vs
26.5 kg/m2,p = 0.03).Mean portal pressure post-islet
infusion was higher in patients with PVT (25.2 vs
16.0,p = 0.0007), with 4/9 having pressures over 30 mmHg.
The median time to diagnosis of PVT was 10.5 days
postoperative(range 7 to 210),with 7/9 having negative
duplex POD1. Eight of 9 patients with PVT were treated
with systemic anticoagulation and 7/8 had resolution on
repeat imaging. One patient died from complications of
anticoagulation. Two patients developed cavernous
transformation(CTPV), one untreated and one diagnosed
after CTPV. All patients with PVT were insulin-requiring at
latest follow-up versus 72/94 patients(77%) without PVT
with at least 1-year follow-up(p = 0.035).
Conclusions: PVT following TPIAT is an uncommon but
serious complication. It occurs late in the postoperative
period in women with a low BMI. A standardized follow-up
imaging protocol is suggested. The treatment for PVT
is anticoagulation. Patients with PVT can expect to be
insulin-dependent.
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OP-II.25 READMISSION AFTER
PANCREATECTOMY FOR CANCER;
A DATA-DRIVEN APPROACH TO
QUALITY IMPROVEMENT
S. M. Misustin, K. K. Christians, F. M. Johnston,
E. A. Krzywda, S. L. Lahiff, S. Tsai, D. B. Evans
Medical College Of Wisconsin, Milwaukee, WI
Background: Hospital readmissions have been proposed as
a hospital quality measure. Analysis of readmissions has
largely focused on post-discharge management. Assessment
of pre-discharge data may reveal additional information.
Methods: Pancreatic cancer (PC) pts who underwent resec-
tion were identified. The causes of readmissions within 30
days of discharge were reviewed.
Results: Surgical resection was performed on 210 consecu-
tive pts. The median length of stay of the index operation was
8 days (IQR: 4). Postoperative complications were identified
during the index hospitalization in 45 (22%) pts, with one
perioperative death. Pts were discharged to: home with
family (48; 23%), home with visiting nurse (144; 69%), other
facility (15; 8%). Readmission occurred in 29 (14%) pts.
Post-discharge analysis identified 21 (72%) of 29 readmis-
sions related to the operation; infection (6), GI bleed (3),
delayed gastric emptying (3), pancreatic fistula (6), ileus (1),
SBO (2). An additional 8 (28%) of the 29 readmissions
were due to potentially preventable causes including;
hypoglycemia (1), dehydration/anorexia (5), and pain (2).
However, pre-discharge analysis using data available on the
day of discharge suggested that 9 (31%) of the 29 readmis-
sions should not have been discharged and could have been
identified prior to discharge.
Conclusions: Pre-discharge analysis identified data
elements in 9 (31%) of the 29 readmissions that could have
prevented discharge, but were undetected in post-discharge
analysis. To prospectively identify these pts prior to dis-
charge, the causes of these 29 readmissions were used to
create a checklist and a formal “time out” discharge pro-
cedure has been implemented.
OP-II.26 TITLE
D. P. Nussbaum, L. M. Youngwirth, R. R. White,
B. M. Clary, J. A. Sosa, D. G. Blazer
Duke University Medical Center, Durham, NORTH
CAROLINA
Introduction: Pancreatic acinar cell carcinoma (pACC) has
cure rates up to 40% following resection, yet many patients
with localized disease do not undergo surgery.
Methods: The 1998–2011 National Cancer Data Base was
queried for patients with pACC. Among patients with local-
ized disease, multivariable analysis was used to predict the
likelihood of undergoing resection. Cox proportional hazards
modeling was then used to assess variables associated with
survival following resection.
Results: 933 patients were identified. Median age at diag-
nosis was 64 years. Tumors were most common in men
(66%) and white patients (88%), and occurred most fre-
quently in the pancreatic head (57%). Mean size was 6.6 cm.
While 42% of patients presented with localized disease,
nearly one-quarter of these patients did not undergo resec-
tion. Median survival was 55 months following resection,
compared to 23 months without surgery (p < 0.01). Failure to
undergo surgery was associated with older age (OR 1.32,
p = 0.02), male sex (OR 2.30, p < 0.01), black race (OR 2.86,
p = 0.03), higher grade (OR 2.45, p = 0.03), location within
the head (OR 3.33, p < 0.01), and treatment at a non-
academic facility (OR 2.09, p < 0.01). Following adjustment,
only older age (HR 1.17, p = 0.01) and lymph node metas-
tases (HR 2.58, p = 0.04) were associated with increased
mortality following resection (Table 1).
Conclusions: Survival following resection of pACC is
nearly five years, yet specific subsets of patients appear less
likely to undergo surgery. Of these groups, only older age is
independently associated with mortality. Efforts to increase
access to care could result in improvements in survival for
patients with pACC.
OP-II.27 RADIOGRAPHIC RESPONSE
AND RESECTABILITY OF LOCALLY
ADVANCED, BORDERLINE RESECTABLE
PANCREATIC ADENOCARCINOMA
AFTER EXTENDED NEOADJUVANT
CHEMOTHERAPY
J. Clanton, J. B. Rose, A. Alseidi, T. Biehl, S. Helton,
F. Rocha
Virginia Mason Medical Center, Seattle, WA
Background: Neoadjuvant therapy is often utilized for
locally advanced, borderline resectable pancreatic cancer
(BR-LAPD) prior to resection, despite previous reports sug-
gesting minimal downstaging. However little is known about
the effect of extended preoperative chemotherapy on disease
response.
Methods: Retrospective review of a prospective database of
consecutive patients with BR-LAPD treated with a 24-week
course of gemcitabine and docetaxel between 2011 and 2014
was performed. Patients with high-quality imaging before
and after treatment, and who completed full course of
therapy with intention to resect were included. RECIST 1.1
criteria were used to assess radiographic response.
Results: Forty-five patients who completed extended
neoadjuvant chemotherapy were included for analysis.
Thirty-two (71.1%) patients underwent pancreatico-
duodenectomy and 14 (31.1%) received a vein resection.
Thirteen (28.9%) were not resected due to local or distant
progression or reduced performance status. The majority of
patients demonstrated stable tumor size (24/45, 53.3%) or
partial response (20/45, 44.4%). Suspicious lymph nodes
remained stable (27/45, 60%) or improved (11/45, 24.4%)
while vascular involvement was stable (21/45, 46.7%) or
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improved (16/45, 35.6%) after treatment. None of the ten
patients not resected after chemotherapy had an increased
tumor size, three had enlarging lymph nodes, and one had
more extensive vascular involvement by CT. None of these
factors were associated with ability to undergo resection
(p > 0.05)
Conclusions: Extended neoadjuvant chemotherapy for
BR-LAPD commonly results in either stable disease or a
partial response. One-third of patients have demonstrable
downstaging of vascular involvement, however radiographic
response or downstaging is not associated with successful
resection.
OP-II.28 PATIENT SELECTION FOR
ROBOT-ASSISTED
PANCREATODUODENECTOMY
FAVOURS OBESITY
N. Ali, A. T. Stafford, G. Morris-Stiff, J. Wey, K. ElHayek,
S. Chalikonda, R. M. Walsh
Department Of HPB Surgery, Cleveland, OHIO
Introduction: There are potential advantages to the
application of minimally invasive techniques to pancrea-
toduodenectomy (PD), with current data indicating its tech-
nical feasibility. We present a single center experience of
robot-assisted PD (RAPD) focusing on patient selection and
outcomes, in particular infections, comparing results to open
PD.
Methods: A retrospective review of a prospectively main-
tained database of all open PDs and RAPDs from March
2009 to June 2014 was performed. RAPD has been intro-
duced selectively during this period. As the main outcome
assessment was infection rate (total/deep organ space and
surgical site [SSI]), patients converted from RAPD to open
were included in the open group.
Results: 69 patients underwent completed RAPD, and 372
open PD during the study period. There was a change in
disease etiology from predominantly premalignant lesions
and ampullary carcinomas to include all indications for PD.
There was a significant difference in BMI between groups
with RAPD preferentially used in obese patients (p = 0.004)
that evolved during the study. Comparing RAPD and open
PD, the SSI rate was less in the RAPD group (9% vs.14%)
with no difference in overall infective complication rate
(26% vs. 26%) or intra-abdominal infection (10% vs. 10%).
Estimated blood loss was significantly less (200 versus
400 cc (p < 0.001) in favor of RAPD.
Conclusion: Increasing experience with RAPD has led to a
change in utilization of the procedure and a transition to its
use in all pathologies. To maximize its benefits we have a
positive selection bias towards obese patients.
OP-II.29 PREDICTORS OF ACTUAL
SURVIVAL IN RESECTED
PANCREATIC ADENOCARCINOMA:
A POPULATION-LEVEL ANALYSIS
D. J. Kagedan1,2, R. Raju2, M. Dixon3, E. Shin1, Q. Li5,
N. Liu5, M. Elmi1,2, A. El-Sedfy4, C. Earle2, N. Mittmann2,
N. G. Coburn2
1University Of Toronto, Toronto, ON; 2Sunnybrook Health
Sciences Centre, Toronto, ON; 3Maimonides Medical
Center, Brooklyn, NY; 4Saint Barnabas Medical Center,
Livingston, NJ; 5Institute For Clinical Evaluative Sciences,
Toronto, ON
Introduction: Among patients diagnosed with pancreatic
adenocarcinoma, numerous clinicopathologic factors have
prognostic value following curative-intent resection. We
sought to assess actual survival following resection and to
determine factors predictive of survival on a population level.
Methods: Patients undergoing resection for pancreatic
adenocarcinoma between 2005–10 were identified within the
provincial cancer registry and administrative databases that
include actual survival for all patients in Ontario, Canada
(population 13 million). We fully abstracted pathology
reports for 473. Kaplan-Meier survival analysis and Cox
proportional hazards multivariate regression were performed
to determine the clinicopathologic variables associated with
decreased survival.
Results: The actual 1-, 3-, and 5-year survival rates were
65%, 23%, and 15% respectively, with median survival 1.48
years. Follow-up time ranged from 2.07–7.22 years, and 377
(79.7%) were censored for death before the end of follow-up.
Multivariate regression revealed the following variables to be
negatively associated with survival: age >70 (p = 0.001), T
stage (p < 0.01), nodal metastasis (p < 0.001), tumor grade
(p < 0.001), positive margin status (p < 0.01), lympho-
vascular invasion (p < 0.001), lymph node positivity ratio
>0.2 (p < 0.001). Patients with multivisceral or major vascu-
lar resections, and patients with low socioeconomic status
did not have worse survival. Receiving treatment at a
high-volume hepatopancreatobiliary center was associated
with improved survival (HR = 0.49, 95%CI = 0.36–0.67,
p < 0.0001).
Conclusion: Advanced age, positive margins, and histo-
pathologic tumor characteristics predict poor prognosis, and
undergoing more extensive resection does not worsen
survival. Receiving treatment at a hepatopancreatobiliary
centre improves survival. In a publicly-funded health-
care system, poor socioeconomic status does not worsen
survival.
OP-II.30 DOES THE MD ANDERSON
(MDA) CRITERIA OF BORDERLINE
RESECTABLE (BLR) PANCREATIC
CANCER IMPACT SUCCESSFUL
COMPLETION OF NEOADJUVANT
THERAPY AND SURVIVAL?
A. N. Krepline, K. K. Christians, B. George, P. S. Ritch,
B. A. Erickson, K. Oshima, P. Tolat, D. B. Evans, S. Tsai
Medical College Of Wisconsin, Milwaukee, WI
Background: BLR PC has been classified based on tumor-
vessel abutment/encasement or the radiographic presence of
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indeterminate metastatic lesions. The importance of this sub-
classification on outcome is unclear.
Methods: BLR PC patients were classified as: type A, ana-
tomic criteria; type B, indeterminate CT findings including
suspicious peripancreatic lymphadenopathy (LAD), or a
CA19-9 >2000 (hiCa19-9). Patients meeting both type A and
B criteria were classified as type B.
Results: Of the 110 BLR patients, 56 (51%) were type A and
54 (49%) were type B. Restaging after neoadjuvant therapy
(Neoadj), demonstrated metastases in 8 (14%) of 56 type A
vs. 11 (20%) of 54 type B patients (p = 0.82). Neoadj and
surgery (Surg) was completed in 66 (60%) of the 110
patients; 37 (66%) type A and 29 (54%) type B (p = 0.19). Of
the 54 type B patients, Neoadj and Surg was successfully
completed in: 8 (42%) of 19 with indeterminate CT findings;
15 (56%) of 27 with suspicious LAD; and 6 (86%) of 7 with
hiCa19-9 (p = 0.14). Overall survival (OS) for type A vs. B
patients was 17 vs.19 months (p = 0.93). Of the 66 patients
who completed Neoadj + Surg, type A and B patients had OS
of 31 vs. 42 months respectively (p = 0.38); there were no OS
differences between type B subgroups.
Conclusions: In a contemporary series of 110 pts with BLR
PC, 60% completed neoadjuvant therapy including surgery.
Subgroup categorization of BLR patients into type A and B
had no prognostic significance.
OP-II.31 THE IMPACT OF MINIMALLY
INVASIVE DISTAL PANCREATECTOMY
ON 90-DAY READMISSIONS AND COST:
IS IT ANY BETTER THAN OPEN?
J. Parikh, S. Anantha Sathyanarayana, S. Bendix,
M. J. Jacobs
Providence Hospital Medical Center, Southfield, MI
Introduction: Laparoscopic distal pancreatectomy (LDP) is
commonly performed for lesions of pancreatic body and tail.
Surprisingly, recent literature suggests an increase in read-
mission rates after LDP, hence potentially negating any
gained length of stay (LOS) benefit compared to open distal
pancreatectomy (ODP). Therefore, we sought to examine
readmission rates and total cost of LDP versus ODP at a
high-volume community hospital.
Methods: Between January 2003 to December 2013, 81
distal pancreatectomies were performed at a community
teaching hospital. A retrospective analysis on demographics,
90-day outcomes, readmission rates, length of stay (LOS),
and total cost were collected.
Results: Eighty-one patients underwent distal pancreatec-
tomy (41 open and 40 laparoscopic). Median age was 62
years. Two-thirds of patients were female. LDP had signifi-
cantly shorter mean operative time (150 vs. 183 minutes;
p < 0.01) and decreased blood loss compared to ODP (135
vs. 568 mL; p < 0.001). Table 1 compares tumor character-
istics, LOS, readmission rates, and costs. Pancreatic fistula
rates were comparable with no Grade C fistulae in either
group. Overall 90-day morbidity was lower in the LDP group
with no mortalities. The 30-day and 90-day readmission rate
was lower in LDP; hence LDP has lower total hospital days.
The overall costs for both the index admission and the total
hospital stay (including readmission) were lower for LDP
group.
Conclusion: LDP has significantly lower index LOS, fewer
total hospital days and lower overall costs compared to ODP.
LDP should be the standard of care for amenable lesions in
the body or tail of the pancreas.
OP-II.32 SHOULD SMALL PANCREATIC
NEUROENDOCRINE TUMORS BE
OBSERVED OR RESECTED?
R. E. Eldert, N. Valsangkar, M. Kilbane, J. L. Cioffi,
M. G. House, N. J. Zyromski, C. M. Schmidt, A. Nakeeb,
E. P. Ceppa
Indiana University School Of Medicine, Indianapolis, IN
Background: Pancreatic Neuroendocrine Tumors (PNET)
are heterogeneous in behavior and metastatic potential.
Recent series recommend surveillance of PNET less than
2 cm in size; consensus is lacking whether a size cutoff for
PNET can be used to define malignant potential and guide
therapy. The aim of this study was to determine if there were
differences in cancer-specific outcomes following resection
for tumors 2 cm or less versus greater than 2 cm.
Methods: Consecutive cases of resected nonfunctional
PNET (n = 48) were reviewed retrospectively at a high
volume academic center between 2004 and 2009. Data were
gathered through the American College of Surgeons-
National Surgical Quality Improvement Program and elec-
tronic medical records. Survival was determined from the
institutional cancer registry and Social Security Death Index.
Results: Patients with PNET 2 cm or less (n = 16) versus
those greater than 2 cm (n = 32) had no significant difference
in demographic, preoperative, or intraoperative variables.
Surgical pathology was reviewed (Table). Patients underwent
distal pancreatectomy (56%), pancreaticoduodenectomy
(29%), enucleation (8%), central pancreatectomy (4%), and
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Frey-procedure (2%). Mortality at 30 and 90 days was 0% for
both groups. The 2 cm or less group had a lower 30-day and
90-day morbidity (p < 0.01). There was no significant differ-
ence in five-year survival between groups.
Conclusions: Resected nonfunctional PNET 2 cm or less
appear to have a similar rate of lymph node and distant
metastasis and no significant benefit of 5 year survival com-
pared to larger PNETs. The lower rate of postoperative mor-
bidity and equivalent overall malignant nature of PNET
supports resection over observation of PNET 2 cm or less.
OP-II.33 CHOLEDOCHODUODENOSTOMY
IS A SAFE AND EFFICIENT
ALTERNATIVE FOR BILE DUCT
RECONSTRUCTION DURING
LIVER TRANSPLANT
T. L. Nydam
University Of Colorado School Of Medicine, Aurora, CO
In our institution, choledochoduodenostomy (CDD) has
become the bile duct reconstruction of choice in liver trans-
plants when a duct-to-duct choledochocholedocostomy
(D2D) is not possible. We provide evidence that CDD is a
safe option for bile duct reconstruction with significant
advantages during postoperative care.
Methods: All orthotopic liver transplants performed at The
University of Colorado Hospital from July 2006 to July 2013
were retrospectively reviewed. Patient demographics, donor
type, post-transplant complications, ERCP times, and biliary
percutaneous transhepatic interventions (PTC) were col-
lected. Statistical analysis was performed using a paired
student’s t-test assuming equal variances.
Results: 632 liver transplants were performed. Eighty-two
patients underwent CDD, 28 patients underwent Roux en Y
choledochojejunostomy (CDJ), and 522 patients underwent
D2D. There was no statistical difference in cholangitis, bile
leak, anastomotic stricture, or other complications. However,
there was a statistically significant difference in mean length
of ERCP and number of PTCs between the CDD and CDJ
cohorts. (Table 1).
Conclusions: Contrary to traditional teaching, a CDD
reconstruction appears to have no difference in complications
compared to a CDJ reconstruction. In addition, the length of
time spent during ERCP and the number of PTCs required
were significantly lower in the CDD cohort. In our institu-
tion, CDD is a safe option for bile duct reconstruction during
liver transplant that provides improved postoperative access
to the graft biliary system.
OP-II.34 A PILOT STUDY OF ADJUVANT
SORAFENIB IN HIGH RISK LIVER
TRANSPLANTATION FOR HCC
A. E. Alsina1,2, E. S. Franco1,2, A. Makris4, J. Shim3,
J. Allison3, R. Claudio3, M. Johnstone3, K. Barber5,
C. Albers1, N. Kemmer1
1Tampa General Medical Group, Tampa, FL; 2University
Of South Florida, Department Of Surgery, Morsani
College Of Medicine, Tampa, FL; 3Tampa General
Hospital, Office Of Clinical Research, Tampa, FL;
4University Of South Florida, School Of Business, Tampa,
FL; 5Tampa General Hospital, Tampa, FL
Introduction: Sorafenib can prevent post liver transplant
(LTx) recurrences for hepatocellular carcinoma (HCC) (Yan,
J. Liver Transpl 2013), but data in humans is scarce. We
hypothesized that recurrences in high risk HCC LTx can be
reduced.
Aims: Determine applicability, tolerability, and efficacy.
Methods: Twelve high risk LTx from 2011 to 2014 were
reviewed. Sorafenib started within 2 months if: microvasular
invasion (MVI), beyond Milan, or AFP >500. Dose was esca-
lated from initial 400 mg/d.
Results: 75% were male, average BMI was 31, and 66% had
bilobar tumors. Pathologic staging revealed ave. 2 tumors,
total tumor burden 5.1 cm, 75% either stage B or C (BCLC
staging), and MVI in 42%. AFP was >100 in 17%. Ave. dose
was 265 mg in all patients but 300 mg in those that tolerated
treatment. Four (33%) of patients are still on treatment, but 5
( 42% ) received it for less than 50 days. Side effects included
hand foot syndrome, flushing, anxiety,nausea, diarrhea,
hypertension, neutropenia, arthralgias and abdominal pain.
No recurrences were observed. Eleven (92%) of patients are
alive, all without recurrence.
Conclusion: This pilot study of adjuvant sorafenib post LTx
revealed that 68% of targeted patients received adequate
treatment at tolerable doses of 300 mg daily. Recurrences
were not observed in this high risk group, although follow up
is short. The study gives insight to the current multicenter
sorafenib adjuvant post LTx trial.
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OP-II.35 DIPS VS. TIPS – IS THERE ANY
DIFFERENCE WHEN IT COMES TO
TRANSPLANTATION?
J. L. Pasko, R. C. Schenning, B. D. Petersen, S. L. Orloff
Oregon Health And Science University, Portland, OR
Background: Direct intrahepatic portocaval shunt (DIPS)
is a modification of transjugular intrahepatic portosystemic
shunt (TIPS) commonly used for ESLD patients with
refractory ascites, recurrent variceal bleeding, and end-stage
liver disease. DIPS uses ultrasound guidance to stent a
communication between the IVC and the portal vein. While
TIPS is more readily utilized, DIPS have shown to be
helpful for patients with difficulty anatomy and failed
TIPS.
Objective: To assess whether liver transplantation is safe
and feasible in recipients with DIPS. Secondary aims were to
do a matched comparison of DIPS vs.TIPS transplant recipi-
ents with respect to autologous and PRBC transfusions,
warm ischemia time, cold ischemia time, LOS, graft survival,
and overall patient survival.
Methods: Retrospective review January 1994–December
2011 in a shared two academic institution transplant program
of patients who underwent liver transplantation with an exist-
ing DIPS or TIPS. The transplant operation was either
bicaval (before 2007), or onlay cavacavostomy (after 2008).
Results: Nine DIPS and 27 TIPS patients underwent trans-
plantation during the study period. Nine DIPS were matched
to 18 TIPS patients by age, gender, etiologic disease, and
MELD at transplantation. There was was no statistical dif-
ference in amount of autologous and PRBC blood transfu-
sion, warm ischemia, cold ischemia, LOS, graft survival, or
overall survival.
Conclusion: DIPS when compared to TIPS is safe, and fea-
sible, and carries no added risk to patients undergoing liver
transplantation. Potential liver transplant candidates who are
referred for DIPS based on unfeasible or failed TIPS should
not be denied this treatment option.
OP-II.37 INCIDENCE AND LONG-TERM
SURVIVAL OF PATIENTS WITH
DE-NOVO HEAD AND NECK
CARCINOMA AFTER LIVER
TRANSPLANTATION
A. Andreou1, M. Lenarz2, D. Seehofer1, J. Pratschke1,
A. Coordes2
1Department Of General, Visceral And Transplant Surgery,
Charite Campus Virchow-Klinikum, Berlin, BERLIN;
2Department Of Otorhinolaryngology, Head And Neck
Surgery, Charite Campus Benjamin Franklin, Berlin,
BERLIN
Background: Liver transplant recipients have an increased
risk for the development of de-novo malignancies.
Methods: Clinicopathological data of patients who devel-
oped head and neck cancer after liver transplantation (LT)
were evaluated and predictors for overall survival (OS) were
identified.
Results: Thirty-three of 2040 patients (1.6%) who under-
went LT between 1988 and 2010 developed de-novo
squamous cell carcinoma of head and neck (HNSCC). The
incidence of HNSCC in LT recipients with end stage
alcoholic liver disease was 5%. After a median follow-up of
9 years, 1-, 3-, and 5-year OS rates were 74%, 47% and 34%,
respectively. Tumor size, cervical lymph-node metastasis,
tumor site and tumor therapy (surgery only versus surgery
and adjuvant radio/chemoradiotherapy versus radio/
chemoradiotherapy only, P < 0.0001) were significantly
associated with OS in univariate analysis. However, surgery
only independently predicted OS in multivariate analysis.
Conclusions: Early diagnosis and surgical treatment for
de-novo HNSCC are crucial for outcome. Therefore,
HNSCC risk should be taken into close consideration during
post-transplant follow-up examinations especially among
patients with positive history of smoking and alcohol
consumption.
OP-II.38 IMPACT OF BODY MASS INDEX
ON LIVER TRANSPLANT PATIENT
SURVIVAL: 1994–2013
S. Ayloo1, P. Talbot2, M. Molinari1
1Dalhousie University, Halifax, NS; 2Diabetes Care
Program Of Nova Scotia, Halifax, NS
Back Ground: Obesity is a world-wide epidemic impacting
the field of transplantation. In 2012, more than one-third of
the United States liver transplantations (LT) were performed
on patients with body mass index (BMI) ≥30.
Objectives: To explore the OPTN/UNOS database for
donor and recipient characteristics and transplant outcomes
among first time, whole organ, cadaveric LT patients strati-
fied by different weight-status.
Methods: Retrospective study of the SRTR database from
January 1994 to September 2013 was conducted to analyze
donor/recipient characteristics and transplant outcomes
stratified by underweight (BMI ≤18.5), normal (BMI ≥18.5–
24.99), overweight (BMI 25–29.99), Class I (BMI
30–34.99), class II (BMI 35–39.99) and class III obese (BMI
≥40). Patients with missing BMI were excluded. Transplant
outcomes-Patient survival by Kaplan-Meier, cause of death,
length of hospital stay was analyzed.
Results: Of the 222,000 cases, 66,461 met the inclusion
criteria. The donor characteristics of mean age, median BMI,
cold ischemia time, percent male, Caucasian ethnicity and
leading cause of death of head trauma were 40 years,
25.4(7.4–73.22), 7 hours(0–49.5), 60%, 71% and 41%
respectively. Recipient characteristics and outcomes are pre-
sented in Table 1. Kaplan-Meier shows lower survival for
underweight and obese. BMI is significantly associated with
gender, ethnicity, education, functional status, primary diag-
nosis, comorbidities, graft failure (acute/de novo hepatitis),
primary cause of death.
Conclusion: LT in obese patients is increasing, with
increasing proportion of NASH as an indication for trans-
plantation. Cardiovascular events were significantly higher in
higher BMI groups. Patient survival was lower in under-
weight and obese Class III in comparison to other BMI
grouping.
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OP-II.39 THE EFFECT OF A PORTAL
PRESSURE < 15 ON THE PREVENTION
OF SMALL-FOR-SIZE SYNDROME IN
ADULT-TO-ADULT LIVING-DONOR
LIVER TRANSPLANTATION: AN
OBSERVATIONAL STUDY
A. S. Helmy1, A. Abdelhady1, A. Hosny1, A. Dahaba3,
M. A. Al-Shazly1, M. El-mansy2, S. Uemoto4
1Cairo University, Cairo, GIZA; 2Department Of Clinical
Pathology, Theodor Bilharz Research Institute, Cairo,
GIZA; 3Department Of Anaesthesiology And Intensive Care
Medecine, Graz, GRAZ; 4Department Of Surgery, Division
Of HPB Surgery And Transplantation, Graduate School Of
Medicine, Kyoto, KYOTO
Background: Small-for-size liver graft injury in Adult-to-
adult living-donor liver transplantation (A-LDLT) can con-
tribute to severe postoperative graft dysfunction, known as
Small-for-size syndrome (SFSS). Recent evidence implicates
portal hypertension in SFSS pathogenesis. The aim of our
study was to investigate the effect of a portal venous pressure
(PVP) cut-off value of <15 mmHg on the prevention of SFSS
in A-LDLT.
Methods: Thirty-three patients underwent A-LDLT
between October 2009 and June 2013. We aimed to keep the
PVP under 20 mmHg at the end of the operation using graft
inflow modulation (GIM). Patients fell into 2 groups; group
A with final PVP <15 mmHg (n = 16) and group B with final
PVP ≥15 mmHg (n = 17). We diagnosed postoperative SFSS
according to the Clavien definition.
Results: Final PVP was controlled under 20 mmHg in all
patients. Three patients suffered SFSS in group B (17.6%)
compared with no patients in group A (P = 0.078). There was
a higher proportion of dead patients in group B [4, two of
whom died of SFSS (23.5%)] versus group A [1 (6.2%);
P = 0.166].
Conclusion: A final PVP <15 mmHg correlates with better
outcomes and seems to be a safe target level for the preven-
tion of postoperative SFSS in A-LDLT.
OP-II.40 COMPLETE PATHOLOGIC
TUMOR KILL IS NOT REQUIRED AFTER
BRIDGING THERAPY FOR HCC
E. Beal, S. Black, M. Bloomston, C. Schmidt
The Ohio State University, Columbus, OH
Introduction: In patients with hepatocellular carcinoma
(HCC), bridging therapy is common prior to liver transplant
(LT) using ablation or trans-arterial chemoembolization
(TACE). It is unknown whether complete pathologic tumor
kill is needed for superior outcome.
Methods: The medical records of all patients who under-
went LT between 2008 and 2013 at a single hospital were
reviewed. The incidence of viable HCC within the hepatic
explant was determined for patients who underwent LT after
bridging therapy. Outcomes were compared between those
with complete and incomplete tumor kill.
Results: There were 125 patients who underwent LT during
the study period, and 42 (34%) had HCC. Twenty-eight
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(65%) were treated with bridging therapy, specifically 13
(46%) underwent ablation and 15 (54%) underwent TACE.
Viable tumor within the hepatic explant was found in 11
(69%) patients after ablation and 10 (67%) after TACE.
Median follow-up after LT in the HCC group was 17.3
months. Estimated 5-year survival was similar in the ablation
(75%) and TACE (76%) groups. One death occurred in the
perioperative period (3%). There was one patient with recur-
rent cancer in the cohort initially treated with ablation who
died 13.3 months after LT with multifocal disease.
Conclusions: After bridging therapy with either ablation or
TACE, rates of viable HCC are high in the explant after LT.
Despite this, recurrence is uncommon and overall survival is
comparable to patients transplanted without HCC. Depend-
ing on regional waitlist mortality, it may not always be nec-
essary to achieve complete pathologic tumor kill with
bridging therapy.
OP-II.41 EXPANSION OF HPB AND
LIVER TRANSPLANTATION IN AN
UNDERSERVED STATE: CREATING
GROWTH AND MAINTAINING QUALITY
C. D. Anderson, A. Seawright, B. Borg, T. M. Earl
University Of Mississippi Medical Center, Jackson, MS
Significant disparities in HPB/liver transplant care prompted
expansion of Mississippi’s only transplant program. The stra-
tegic plan hypothesized that a systems based approach would
allow growth while maintaining quality.
Methods: Systems were implemented to start the program
in 8/2011 including a streamlined transplant clinic, increased
outreach, a robust QAPI system, and the creation of a liver
tumor program. This study examined institutional wide data
from 1/1/2010 until 3/31/2014. Period 1 (1/1/2010–7/31/
2011) represented pre-expansion, and period 2 (1/1/2013–3/
31/2014) was after full implementation. The performance of
the liver tumor, and liver transplant programs was analyzed.
Data is reported by median. Periods are compared using the
student t-test.
Results: From 8/2011 until 3/2014, 222 patients with liver
tumors were evaluated. Loco-regional liver tumor treatments
increased from 5/quarter to 25/quarter (p < 0.001). Major
HPB operations increased from 3/quarter to 14/quarter
(p < 0.001). This increase was within the transplant program
(14 vs 2/quarter). The first liver transplant occurred in
3/2013. 29 liver transplants were performed in 13 months.
1-month allograft and patient survivals were 93% and 100%.
Actuarial 1-year allograft and patient survivals were 89.66%
and 96.55%. MELD at transplant was 22 (range 15–40). 35%
of transplant recipients were African American (13% region-
ally, 10% nationally). LOS was 9 days. 30 day readmission
was 20.69%.
Conclusion: A disparity in HPB and liver transplant access
existed in Mississippi which was addressed via a comprehen-
sive expansion of the abdominal transplant programs. The
approach allowed rapid creation of a high volume transplant/
HPB center and improved patient access while maintaining
expected outcome metrics.
OP-II.43 RACIAL DISPARITY IN LIVER
TRANSPLANTATION IN AN INNER
CITY POPULATION
A. Smith, A. T. Hauch, E. Kandil, A. Paramesh,
M. Killackey, M. Moehlen, L. A. Balart, J. F. Buell
Tulane Transplant Institute, Tulane University And
Louisiana State University Medical System, New Orleans,
LA
Several studies have identified disparity in access to liver
transplantation among African Americans. This study exam-
ines the experience of an inner city University transplant
program with a significant proportion of socioeconomically
challenged African American patients.
Methods: A retrospective analysis of all liver transplant
(LT) recipients at our institution from 2007–2014. Pre-
transplant demographics and post-transplant outcomes were
analyzed. A multivariate analysis was performed to examine
patient and graft survival as well as risk for complications.
Conclusions: African American patients that were success-
fully transplanted at our institution were significantly
younger with trends of lower portal vein thrombosis and
acutely decompensated (higher INR, inpatient transplant
event). Despite limited evidence these data suggest a selec-
tion bias. To further delineate the origins of this bias we plan
on further analyzing waitlist mortalities and dropout events
along racial lines to identify if African Americans are at
higher risk for dropout under this current allocation system.
OP-II.44 ADDITION OF STEREOTACTIC
BODY RADIATION TO PREVENT LIVER
TRANSPLANT WAITLIST DROPOUT:
IS IT SAFE?
T. J. Smith3, J. E. Hooper6, A. E. Castillo1,2, W. Naugler5,
P. Worth1,2, K. Kolbeck7, K. Farsad7, K. Enestvedt1,2,
M. Fuss4, T. Mitin4, C. Thomas4, S. Orloff1,2
1Oregon Health And Science University. Department Of
Surgery, Portland, OR; 2Portland VA Medical Center.
Department Of Surgery, Portland, OR; 3Gundersen Health
System. Department Of Surgery, La Crosse, WI; 4Oregon
Health And Science University. Department Of Radiation
Oncology, Portland, OR; 5Oregon Health And Science
University. Department Of Medicine, Portland, OR; 6Johns
Hopkins. Department Of Pathology, Baltimore, MD;
7Oregon Health And Science University. Department Of
Radiology, Portland, OR
Background: Waitlist dropout is a major consideration in
liver transplantation (LT) for HCC. Loco-regional treatment
is used to prevent dropout. Little is known about Stereotactic
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Body Radiation (SBRT) safety and its influence on waitlist
dropout, perioperative LT complications, or recurrence
post-LT.
Aim: Whether adding SBRT to HCC LT waitlist pati-
ents having received Trans-Arterial-Chemo-Embolization
(TACE), impacts the safety/efficacy profile as measured by
waitlist dropout, perioperative complications or post-
transplant HCC recurrence.
Methods: Retrospective analysis from a two-institution
transplant program, of 10 consecutive waitlisted HCC
patients receiving SBRT + TACE matched with 10 such
patients receiving TACE only.
Results: Median treatment follow-up: SBRT + TACE group
45 vs 43 mo TACE-only group; median LT follow-up: 34 and
38 mo, respectively. Mean wait-time for the SBRT-group was
330 d vs 150 d for the TACE-only group. At last follow-up
8/10 SBRT-group patients were alive vs 6/10 in the TACE-
only group. One HCC recurrence occurred in the SBRT-
group vs two in the TACE-only group. All HCC recurrences
died. Pre-transplant median AFP was higher in the SBRT-
group. Tumor response by explant percent necrosis was
similar between groups. LOS, ICU days and median EBL
trended higher for the SBRT group (p = 0.60). There were no
waitlist drop-outs in either group.
Conclusions: Despite longer waitlist time, HCC patients
receiving SBRT + TACE had no waitlist drop-out, and lower
HCC recurrence post-LT. SBRT + TACE patients trended
toward more difficult operations, but no significant difference
in post-LT survival. Thus, addition of pre-LT SBRT to TACE
appears safe and effective as a bridge to LT. Future prospec-
tive randomized clinical trials are warranted.
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VIDEO A – LIVER
V-A.01 TIPS AND TRICKS FOR
GLISSONIAN APPROACH DURING
LAPAROSCOPIC RIGHT HEPATECTOMY
F. F. Makdissi, R. C. Surjan, M. A. Machado
Sirio Libanes Hospital, Sao Paulo, SAO PAULO
Background: Laparoscopic Glissonian approach is a tech-
nique that avoids dissection of the hilar plate. It is useful for
anatomical liver resection and can reduce the operative time.
However, it has not been frequently used because needs
expertise and knowledge of liver anatomy.
Aim: To present a video of a laparoscopic right hepatectomy
using the Glissonian approach. The detailed technique for
control of the right pedicle is highlighted in this video.
Patient and Methods: A 29-year-old man with anabolic
steroids abuse presented with an acute abdominal pain. CT
scan showed 11-cm mass in the right liver. Patient is referred
for surgical treatment. Operation begins with liver mobiliza-
tion. Glissonian approach of the right pedicle is achieved
with two small incisions made in specific anatomic land-
marks around hilar plate. Clamp is introduced through these
incisions to occlude right Glissonian pedicle. The vascular
clamp is then replaced by an endoscopic vascular stapling
device, the right liver ischemic delineation is confirmed, and
the stapler is fired. All of these steps are performed without
the Pringle maneuver and without hand assistance. Liver
transection and vascular control of the right hepatic vein are
accomplished with as usual. The specimen is extracted
through suprapubic incision.
Results: Operative time was 160 minutes with minimum
blood loss. Recovery was uneventful and patient was dis-
charged on the third postoperative day. Final pathology
showed liver cell adenoma with no signs of malignancy and
free margins.
Conclusion: Laparoscopic Glissonian approach for right
hepatectomy is safe, fast and can be accomplished with
proper technique.
V-A.02 CAVO-ATRIAL THROMBECTOMY
COMBINED WITH RIGHT
HEPATECTOMY EXTENDED TO
SEGMENT IV FOR VASCULAR INVASION
FROM HEPATOCELLULAR CARCINOMA
THROUGH AN ABDOMINAL,
TRANSDIAPHRAGMATIC AND
INTRAPERICARDIAC APPROACH
E. Vicente1,2,3, Y. Quijano1,2,3, B. Ielpo1,2,3, H. Duran1,2,3,
I. Fabra1,2,3, E. Diaz1,2,3, S. Olivares1,2,3, R. Caruso1,2,3,
A. Prestera1,2,3, M. De Luca1,2,3, J. Maupoey1,2,3,
E. Vicente1,2,3
1Sanchinarro University Hospital., Madrid, MADRID;
2Clara Campal Oncological Center, Madrid, MADRID;
3San Pablo University. CEU, Madrid, MADRID
Vascular invasion of supra-hepatic veins is a major compli-
cation of primary liver tumours. The tumoral thrombus, when
extended to the vena cava and right atrium, may produce
occlusion of the tricuspid valve or pulmonary embolism with
sudden cardiac death. The presence of macroscopic vascular
infiltration represents an advanced stage of the tumour
contraindicating liver transplantation, thus liver resection
with thrombectomy is the only therapeutic option in this
setting despite the concerns of postoperative liver failure and
the dismal results at distance A 62-year-old female without
chronic liver disease was referred to our Hospital diagnosed
of the tumour located in the right hemi-liver with infiltration
of the right hepatic veins and a tumour thrombus extension to
the retrohepatic and suprahepatic inferior vena cava and right
atrium. Routine blood tests revealed normal hematological
results and liver biochemistry function. A computed tomog-
raphy (CT) scan, Nuclear magnetic resonance (MRI) dem-
onstrated the tliver tumor and the thrombus extending into
retrohepatic, supraphrenic-intrapericardial IVC and right
atrium. Right portal vein embolization was performed before
the surgical resection The video shows the preoperative diag-
nostic procedures to evaluate the location of the tumor, the
vascular invasion and extent of thrombus as well as the sur-
gical procedure. Through a bilateral subcostal laparotomy,
right hepatectomy extended to segment IV was performed.
The transabdominal and transpericardial approach to the
intrapericardial IVC and right atrium avoided median
sternotomy. Intravascular trombectomy with intraoperative
transesophageal echocardiogram was also performed. Two
years after the operation, the patient remains alive and well
without evidence of tumoral recurrence.
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